2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1440

Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Abstract Number: 2346

Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Abstract Number: 2839

Effects Of Treatment On Spinal Fat Lesions As Assessed By MRI With The Fat Spondyloarthritis Spine Score
Abstract Number: 2350

Effects Of VX-509, An Investigational Oral Selective Janus Kinase 3 (JAK3) Inhibitor, On Patient-Reported Outcomes In a Phase 2A Study Of Patients With Active Rheumatoid Arthritis
Abstract Number: 443

Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
Abstract Number: 1422

Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis
Abstract Number: 793

Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Abstract Number: 1591

Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Abstract Number: 2028

Efficacy and Safety Of Biologic Agents In Adult-Onset Still’s Disease: A Long-Term Follow-Up Of 19 Patients At a Single Referral Center
Abstract Number: 2165

Efficacy and Safety Of Biologic Agents In Patients With Poly-Articular Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Controlled Withdrawal Trials
Abstract Number: 1339

Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Abstract Number: 1177

Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Abstract Number: L15

Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
Abstract Number: L1

Efficacy and Safety of CT-P13 (Infliximab biosimilar) over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13
Abstract Number: 499

Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].